Showing results (1291-1300 of 1,306) with videos related to

Sort By:
Pageof 131
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning MeetingRitu R Gill, Anne S Tsao, Hedy L Kindler, et al.
BMJ Global Health|October 23, 2024
Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trialCharles J Gerardo, Rebecca W Carter, Surendra Kumar, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|February 14, 2021
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Radiology|April 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
The Lancet. Oncology|April 15, 2024
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The New England Journal of Medicine|August 30, 2008
Toll-like receptor 3 and geographic atrophy in age-related macular degenerationZhenglin Yang, Charity Stratton, Peter J Francis, et al.
Cell|March 20, 2025
Growth of the maternal intestine during reproductionTomotsune Ameku, Anna Laddach, Hannah Beckwith, et al.
Pageof 131